We are monitoring the impact of COVID-19 on APAC Liquid Biopsy Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 892
Share on
Share on

Asia Pacific Liquid Biopsy Market Research Report – Segmented By Cancer Type, Sample Type, Diagnostic Approach, End Users, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2021 to 2026)

Pulished: April, 2021
ID: 892
Pages: 145

APAC Liquid Biopsy Market Size (2021 to 2026)

The Asia Pacific Liquid Biopsy Market size is expected to grow at a CAGR of 31.23% during the forecast period. As a result, the market size is estimated to be worth USD 893.84 million by 2026 from USD 229.67 million in 2021.

Liquid biopsy is a technique that satisfies patients with the best treatment and also doctors by providing potential screening for disease. In addition, molecular characterization of the tumor can also be done by liquid biopsy. It provides ease of repeat sampling for monitoring genetic changes as the procedure is non-invasive.

Medical communities are extending support for the market, which is acting as a key driver. The liquid biopsy technique is under advancement and is continuously improving, helping drive its adoption in clinical applications. Many new technologies are coming up in the market, such as cell capturing, sample preparation, and DNA amplification, making significant progress. However, the rise in technological competition is acting as a restraint for the market.

The test detects cancer accurately with a simple blood test. Liquid Biopsy has a tremendous positive impact on the fight against cancer by reducing the limitations of traditional biopsies. In India, for the first time in the world, tested 20,000 known cancer pathways at Apollo. Around 73% of patients were detected with ctDNA. In India, Neuroendocrine tumors are slow in growth, but they will spread very quickly. GALLIUM 68 SCAN allows surgeons to find the tumor's location. These techniques will promote the liquid biopsy market in the future. The adoption of advanced technology in the medical sector and the launch of innovative products to diagnose cancer at an early stage is accelerating the market's demand.

In China, there are limitations, and the liquid Biopsy can detect not all cancer biomarkers said by some research institutes. China needs more investigations and further validations. However, the demand is increasing for biomarkers in tumor samples. Researches going on liquid Biopsy in the country will create chances for successful business in the future. Increasing chronic disease incidents and present cancer patients will drive the market in the coming years. 

Ministries of Health, Labor, and Welfare in Japan have granted marketing and manufacturing the products used for blood circulating tumor ctDNA molecular testing for colorectal cancer patients. Ongoing research and development programs and the rising number of patients are the major drivers of the liquid biopsy market in Japan.

Australian researchers say that liquid biopsies might be used to treat cancer on a large scale. The Clinical Labs in Australia are proud to aid clinicians and assist patients using advanced technology and a Personalized Medicine approach. It is also beneficial for lung and melanoma patients. So the liquid biopsy market will grow in the future because of the increasing patient count and new player's investments in the market.

In South Korea, biotech companies commercialize the DNA-based liquid biopsy market and enable early cancer detection, precise treatment, and prognostic assessment. The number of patients who have been identified as familial cancer genes with high penetrance will drive the market in the future. Spreading awareness of this market is a challenge for companies. Client relationships and new researches are expected to drive market growth in the forecast period.

This research report on the APAC Liquid Biopsy Market has been segmented and sub-segmented market into the following categories:

By Cancer Type: 

  • Lung Cancer
  • Pancreatic Cancer
  • Leukemia
  • Other Visceral Cancers

By Diagnostic Approach: 

  • Circulating Tumour cells (CTC)
  • Circulating Tumour DNA (ctDNA)
  • RNA in exosomes
  • Extra-Cellular Vesicles

By End-Users: 

  • Reference Laboratories
  • Hospital/Physician Laboratories
  • Academic and Research Centers
  • Other End Users

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, The Asia-Pacific liquid biopsy market is projected to grow highest during the forecast period, primarily due to the increasing focus of players in this region. In addition, India and China are the emerging countries in the Asia-Pacific region. They are expected to grow fast because of increased market access of each country’s population to healthcare resources.

KEY MARKET PLAYERS:

Some promising companies operating in the APAC Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

1. Introduction                                                                 

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                              

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                            

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                     

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                      

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                      

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

5. Market Segmentation                                                                              

                5.1 By Cancer Type                                                         

                                5.1.1 Lung Cancer                                           

                                5.1.2 Pancreatic Cancer                                

                                5.1.3 Leukemia                                

                                5.1.4 Other Visceral Cancers                                       

                5.2 By Sample Type                                                        

                                5.2.1 Blood                                        

                                5.2.2 Urine                                         

                                5.2.3 Plasma                                      

                                5.2.4 Saliva                                         

                                5.2.5 Cerebrospinal                                        

                5.3 By Diagnostic Approach                                                        

                                5.3.1 Circulating Tumour cells (CTC)                                        

                                5.3.2 Circulating Tumour DNA (ctDNA)                                  

                                5.3.3 RNA in exosomes                                 

                                5.3.4 Extra-Cellular Vesicles                                        

                5.4 By End Users                                                             

                                5.4.1 Reference Laboratories                                     

                                5.4.2 Hospital/Physician Laboratories                                     

                                5.4.3 Academic and Research Centers                                    

                                5.4.4 Other End Users                                   

6. Geographical Analysis                                                                              

                6.3 Asia-Pacific                                                 

                                6.1 Introduction                                              

                                6.2 China                                            

                                6.3 India                                              

                                6.4 Japan                                            

                                6.5 South Korea                               

                                6.6 Australia                                      

7. Strategic Analysis                                                                       

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

8. Market Leaders' Analysis                                                                        

                8.1 Janssen Diagnostics                                                

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Qiagen                                                         

                8.3 Rarecells SAS                                                             

                8.4 Silicon Biosystems                                                   

                8.5 SRI International                                                      

                8.6 Myriad Genetics                                                      

                8.7 Natera                                                          

                8.8 Personal Genome Diagnostics                                                            

                8.9 Sysmex Inostics                                                        

                8.10 Trovagene                                                

                8.11 Exosome Diagnostics                                                           

                8.12 HansaBiomed OU                                                  

9. Competitive Landscape                                                                           

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

10. Expert Opinions                                                                        

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Lung Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Leukemia Market, By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Blood Market, By Region, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Urine Market, By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Plasma Market, By Region, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Saliva Market, By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Cerebrospinal Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific RNA in exosomes Market, By Region, From 2021 to 2026 (USD Billion)
  17. Asia-Pacific Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Billion)
  18. Asia-Pacific Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  19. Asia-Pacific Reference Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  20. Asia-Pacific Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Billion)
  21. Asia-Pacific Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Billion)
  22. Asia-Pacific Other End Users Market, By Region, From 2021 to 2026 (USD Billion)
  23. China Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  24. China Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  25. China Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  26. China Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  27. India Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  28. India Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  29. India Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  30. India Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  31. Japan Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  32. Japan Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  33. Japan Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  34. Japan Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  35. South Korea Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  36. South Korea Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  37. South Korea Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  38. South Korea Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)
  39. Australia Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  40. Australia Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Billion)
  41. Australia Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Billion)
  42. Australia Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample